60 Degrees Pharmaceuticals (NASDAQ:SXTP) Posts Earnings Results, Misses Estimates By $0.16 EPS

by · The Markets Daily

60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) announced its earnings results on Friday. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.16), FiscalAI reports. The company had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.18 million.

60 Degrees Pharmaceuticals Trading Up 1.3%

SXTP stock traded up $0.01 during trading on Friday, reaching $1.20. 150,822 shares of the stock were exchanged, compared to its average volume of 1,870,604. The firm’s 50 day moving average is $1.47 and its 200 day moving average is $2.02. The firm has a market cap of $3.18 million, a P/E ratio of -0.13 and a beta of 2.54. 60 Degrees Pharmaceuticals has a twelve month low of $1.05 and a twelve month high of $8.62.

Analyst Ratings Changes

SXTP has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Wednesday, June 24th. Ascendiant Capital Markets dropped their price objective on 60 Degrees Pharmaceuticals from $4.20 to $3.70 and set a “buy” rating on the stock in a research note on Friday, May 22nd. Finally, HC Wainwright cut 60 Degrees Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 20th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $13.85.

Read Our Latest Research Report on 60 Degrees Pharmaceuticals

About 60 Degrees Pharmaceuticals

(Get Free Report)

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.

See Also